
BCTX Stock Forecast & Price Target
BCTX Analyst Ratings
Bulls say
BriaCell Therapeutics Corp has received a significant boost in its financial resources by securing a non-dilutive $2 million grant from the US National Cancer Institute (NCI) to advance its Bria-PROS+ program into clinical stages. This funding will support the manufacturing of clinical supplies and facilitate the Phase 1/2a development for metastatic prostate cancer, further enhancing the company's portfolio of immunotherapies. Additionally, this grant will aid in accelerating the clinical development of Bria-OTS+, which builds on Bria-OTS, currently in a Phase 1/2 clinical trial, highlighting the company’s commitment to advancing innovative cancer therapies.
Bears say
BriaCell Therapeutics faces significant risks impacting its financial outlook, including potential safety signals from clinical programs and the possibility of lower-than-expected efficacy, which could hinder trial successes and overall product development. The company also anticipates a need for substantial additional financing of approximately $120 million through 2037, raising concerns about its ability to meet financial obligations while continuing ongoing research efforts. Furthermore, the presence of increased competition in the market and potential regulatory hurdles further complicate BriaCell's prospects, contributing to a cautious outlook on the stock's future performance.
This aggregate rating is based on analysts' research of BriaCell Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BCTX Analyst Forecast & Price Prediction
Start investing in BCTX
Order type
Buy in
Order amount
Est. shares
0 shares